COMMUNIQUÉS West-GlobeNewswire

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
05/11/2025
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments [...]
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and [...]
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
05/11/2025
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade [...]
CJ Biomaterials signs partnership with BIQ Materials to produce artificial turf infill made with PHACT™ PHA, a certified biodegradable biopolymer, for the European market
05/11/2025
CJ Biomaterials signed an agreement with BIQ Materials, a Swedish biomaterials compounding company, to accelerate the commercialization of PHACT™ PHA-based infill EU ban on intentionally added microplastics including [...]
Alpha Pro Tech, Ltd. Announces Third Quarter 2025 Financial Results
05/11/2025
Overall Third Quarter Sales Increased 3.7% to $14.8 Million, Compared to $14.3 Million for the Third Quarter of 2024 Net sales for the third quarter of 2025 were $14.8 million, up 3.7% compared to $14.3 million for the [...]
Curonix Strengthens Executive Leadership with Appointment of Leading Medical Device Executive Russell Fleeger as Chief Financial Officer to Drive Next Stage of Growth
05/11/2025
POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Curonix LLC (“Curonix” or the “Company”), a medical technology company dedicated to developing and commercializing innovative therapies to relieve chronic pain, [...]
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
05/11/2025
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability [...]
MediWound to Report Third Quarter 2025 Financial Results
05/11/2025
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “ [...]
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
05/11/2025
Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of [...]
Altimmune to Participate in Two Upcoming Investor Conferences
05/11/2025
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
05/11/2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]
Crescent Biopharma to Present at November Investor Conferences
05/11/2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer [...]
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
05/11/2025
Webcast scheduled for Monday, November 10 at 12:00 pm EST REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on [...]
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
05/11/2025
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
05/11/2025
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week [...]
StoryMD Launches “My StoryMD Journeys,” an AI-Powered Health Platform That Transforms an Individual’s Fragmented Medical Records into a Unified and Personalized Health Narrative
05/11/2025
Combines proprietary AI technology with the largest medical content and visual library in the world to empower users across every stage of their health journey NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Today, StoryMD [...]
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
05/11/2025
The target lesion primary patency (TLPP) 1 and access circuit primary patency (ACPP) 2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 [...]
NewGenDigital Appointed as SAXA Inc.’s Agent for Tokenization of US$100 Million of Gold-backed Assets
05/11/2025
Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA’s worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be [...]
Precision Neuroscience and SCI Ventures Partner to Bring Brain–Computer Interfaces to People Living with Paralysis
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a leading brain–computer interface (BCI) company, today announced an investment from SCI Ventures, the world’s first specialist [...]

Pages